858474-14-3
858474-14-3 结构式
基本信息
2-(P-METHOXYPHENYL)-Α-2-PIPERIDYL-4-QUINOLINEMETHANOL DIHYDROCHLORIDE
NSC-23925
2-(P-METHOXYPHENYL)-Α-2-PIPERIDYL-4-QUINOLINEMETHANOL DIHYDROCHLORIDE
2-(4-Methoxyphenyl)-α-2-piperidinyl-4-quinolinemethanol Dihydrochloride
4-Quinolinemethanol, 2-(4-methoxyphenyl)-α-2-piperidinyl-, hydrochloride
(2-(4-Methoxyphenyl)quinolin-4-yl)(piperidin-2-yl)methanol dihydrochloride
[2-(4-Methoxyphenyl)4-quinolinyl]-(piperidin-2-y)-methanol dihydrochloride
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-19626 | 2-(P-METHOXYPHENYL)-Α-2-PIPERIDYL-4-QUINOLINEMETHANOL DIHYDROCHLORIDE NSC23925 | 858474-14-3 | 5mg | 1100元 |
| 2025/05/22 | HY-19626 | 2-(P-METHOXYPHENYL)-Α-2-PIPERIDYL-4-QUINOLINEMETHANOL DIHYDROCHLORIDE NSC23925 | 858474-14-3 | 10mM * 1mLin DMSO | 1210元 |
| 2025/05/22 | HY-19626 | 2-(P-METHOXYPHENYL)-Α-2-PIPERIDYL-4-QUINOLINEMETHANOL DIHYDROCHLORIDE NSC23925 | 858474-14-3 | 10mg | 1900元 |
常见问题列表
P-glycoprotein
NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor. SKOV-3 cells with long-term exposure of 1 μM NSC23925 show stable growth in culture medium. NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment. NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1 µM. The IC 50 for NSC23925 is 8 µM in SKOV-3/SKOV-3 TR and 25 µM in OVCAR8/OVCAR8 TR cell lines, whereas the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3 TR or OVCAR8 TR to cytotoxic drugs is 0.5 µM to 1 µM.
Both saline alone and NSC23925 alone treated tumors grow progressively. The usage of NSC23925 in paclitaxel chemotherapy significantly prolongs anticancer efficacy of paclitaxel.